What is the Semaglutide Injectable Pen (Generic Wegovy)?
The semaglutide injectable pen is an unbranded (generic) version of Wegovy, manufactured by pharmaceutical companies other than Novo Nordisk, the original manufacturer of Wegovy (semaglutide). It is required to demonstrate bioequivalence to the branded product, meaning it contains the same active substance at the same strength and is expected to produce the same clinical effects in the body to help aid weight loss.
Generic medicines become available once the patent protection on the original branded product expires, allowing other manufacturers to produce and market their own versions. Regulatory authorities such as the MHRA require generic medicines to meet strict standards of quality, safety and efficacy before they can be approved for use.
How does the semaglutide injectable pen work?
The semaglutide injectable pen works in the same way as branded Wegovy. Semaglutide is a GLP-1 receptor agonist, meaning it mimics the action of the naturally occurring GLP-1 hormone that is released by the body after eating.
It supports weight loss through several mechanisms:
- Reducing appetite and food cravings, helping you feel satisfied with smaller food portions.
- Slowing gastric emptying, which is the rate at which food leaves the stomach, promoting a longer feeling of fullness after meals.
- Helping to regulate blood sugar levels by stimulating insulin secretion when glucose levels are elevated, which can reduce blood sugar spikes and associated food cravings.
Is the semaglutide injectable pen as effective as branded Wegovy?
Generic medicines are required to demonstrate bioequivalence as the originator product before they can receive regulatory approval. This means that the active ingredient must be absorbed into the body at the same rate and to the same extent as the branded version of the treatment.
In clinical trials, branded semaglutide 2.4 mg (Wegovy) has been shown to produce average weight loss of approximately 15-17% of body weight over 68 weeks. As the generic semaglutide injectable pen contains the same active ingredient at the same dose, it is expected to be as effective at aiding weight loss, although individual results may vary depending on factors such as starting weight, adherence to the dosing schedule and lifestyle modifications.
Is generic semaglutide the same as Wegovy?
Yes. Generic semaglutide contains the same active ingredient, at the same strength, as branded Wegovy. The only differences are the manufacturer, the packaging and the name on the label. A generic version of semaglutide is not expected to contain different active ingredients.
Before a generic medicine can be approved for use in the UK, the manufacturer must demonstrate the same effectiveness and safety profile to the originator product. This means the generic version must be absorbed into the body at the same rate and to the same extent as the branded treatment. The MHRA applies the same standards of quality, safety and efficacy to generic medicines as it does to branded products.
What are the side effects of generic semaglutide?
As generic semaglutide contains the same active ingredient as branded Wegovy, the side effect profile is expected to be the same.
Recommended reading: Wegovy Side Effects: What You Need To Know
Why is generic semaglutide in the news?
Novo Nordisk's core patents on semaglutide have expired or are beginning to expire in several major markets in March 2026, including India, China, Canada, Brazil and Turkey. These countries represent approximately 40% of the global population, and manufacturers in these regions are now able to produce and sell generic versions of semaglutide at significantly reduced cost.
Early reports indicate that generic semaglutide could be priced at 50-60% less than branded equivalents in markets where the patent has expired. The development has attracted widespread media attention, given the global demand for GLP-1 receptor agonist treatments like Wegovy or Mounjaro for weight management.
However, it is important to note that patent expiry is not uniform across all countries, and semaglutide remains under patent protection in the UK, the European Union and the United States.
Is generic semaglutide available in the UK?
No. As of March 2026, generic semaglutide is not available in the UK. Semaglutide remains protected by supplementary protection certificates (SPCs) and secondary patents held by Novo Nordisk in the UK and EU, which extend market exclusivity beyond the expiry of the core compound patent.
These protections mean that generic manufacturers cannot legally market semaglutide in the UK until the relevant patents and SPCs expire, which is not anticipated until the early 2030s. Any generic semaglutide product would also need to receive authorisation from the MHRA before it could be prescribed or dispensed in the UK.
Patients should be aware that purchasing prescription medicines from unregulated sources outside the UK carries significant safety risks. The MHRA advises obtaining prescription-only medicines solely through registered, UK-based pharmacies.
When will generic semaglutide be available in the UK?
The exact date on which generic semaglutide will become available in the UK depends on the expiry of all relevant patents and supplementary protection certificates, as well as the time required for generic manufacturers to obtain MHRA marketing authorisation.
Based on publicly available patent information, generic semaglutide is unlikely to be available in the UK before the early 2030s. However, the patent landscape is subject to change, and legal challenges to secondary patents could potentially bring this date forward.
How much could generic semaglutide cost in the UK?
It is too early to confirm what generic semaglutide will cost in the UK, as no generic version has yet been approved by the MHRA.
However, in markets where the semaglutide patent has already expired, generic versions are launching at 50–60% below the price of branded equivalents, with some reports suggesting costs could fall significantly further as more manufacturers enter the market.
If similar pricing dynamics apply in the UK once generic semaglutide becomes available, it has the potential to offer a considerably cheaper alternative to branded Wegovy. However, the final UK price will depend on a range of factors, including the number of manufacturers entering the market, MHRA approval timelines, NHS commissioning decisions and wholesale supply dynamics.
Where can I buy the semaglutide injectable pen (generic Wegovy)?
The semaglutide injectable pen is not yet available to buy in the UK, as semaglutide remains under patent protection and no generic version has received MHRA marketing authorisation. Once approved for use in the UK, the semaglutide injectable pen is expected to become available through regulated online pharmacies like Pharmica.
You can sign up to be notified to receive updates as soon as the semaglutide injectable pen becomes available in the UK market.
What are the alternatives to generic semaglutide in the UK?
While generic semaglutide is not yet available in the UK, branded semaglutide treatments are currently available through regulated online pharmacies with a valid prescription. These include:
- Wegovy Injectable Pen (Branded Semaglutide) - a once-weekly injection that contains semaglutide that is clinically proven to help lose up to 17% of your body weight when used alongside diet and lifestyle adjustments.
- Mounjaro Injectable Pen (Tirzepatide) - a once-weekly injection that contains tirzepatide that is clinically proven to help lose up to 22.5% of your body weight when used alongside diet and lifestyle adjustments.
Is it safe to buy generic semaglutide from overseas?
The MHRA advises against importing prescription medicines from outside the UK unless they are obtained through a licensed UK pharmacy. Products purchased from unregulated overseas sources may not meet UK quality and safety standards, and there is a risk of receiving counterfeit, contaminated or incorrectly dosed medication.